Navigation Links
BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Date:4/21/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, April 21 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase III MAESTRO-01 Canadian/European trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the final scheduled review by the DSMB prior to the completion of MAESTRO-01. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. Results from MAESTRO-01 are expected in the second half of this year.

    About MAESTRO-01
    ----------------

MAESTRO-01 is a multi-center, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of dirucotide in patients with secondary progressive MS. The study is being conducted at 47 sites across Canada and nine countries in Europe and includes 611 patients being administered either dirucotide or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease, as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 70% of all MS patients are HLA-DR2 and/or HLA-DR4 positive). Time to disease progression in patients with other HLA-DR types will be assessed separately as an exploratory arm of the same study.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multip
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
2. BioMS Medical Announces 2008 Year End Results
3. BioMS Medical warrant extension
4. BioMS Medical to present at BIO CEO and Investor Conference
5. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
6. BioMS Medical recognized at Scrip Awards 2008
7. BioMS Medical Announces Third Quarter 2008 Results
8. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Eckert & Ziegler Vitalea Science (EZVS), a ... the pharmaceutical and biotech industry, has announced that Dr. ... position of Director of Science & Technology. , “Mark ... in drug metabolism and bioanalysis to EZVS in both ...
(Date:1/22/2015)... Mass (PRWEB) January 21, 2015 Cambridge Semantics, ... Web technology, today announced that 2014 was a record-breaking year ... the capabilities of the Anzo Smart Data Platform and our ... and utilize insights from diverse data which led to record ...
(Date:1/22/2015)... zFlo Motion , a US leader ... exciting product from a new partner. STT-Systems has ... past 15 years, with offerings in the optical-motion capture, 3D ... system (inertial measurement unit), iSen, is opening eyes around the ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... 3 Amic AB (Uppsala, Sweden),announced today that ... rights of Roche Diagnostics to commercialise a point-of-care ... NT-proBNP is a key cardiac marker for a ... management of heart failure, and,risk stratification of patients ...
... 2 Exelixis,Inc. (Nasdaq: EXEL ) announced today ... officer, will present at the 26th,Annual JPMorgan Healthcare Conference ... January 10, 2008., The presentation will be webcast ... Investors on the Exelixis website at, http://www.exelixis.com ., ...
... Jan. 2 Nektar,Therapeutics, (Nasdaq: NKTR ) President ... at the upcoming JPMorgan 26th Annual Healthcare,Conference at the ... January 8, 2008, at 4:30 p.m. Pacific Time., ... and slideshow,webcast through a link posted on the Investor ...
Cached Biology Technology:
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., ... a study that pinpoints fine-scale differences in genetic ancestry of ... Since immigrants first arrived more than four hundred ... served as a meeting place for peoples from different continents. ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/11/2014)... 09, 2014 Research and Markets , ... ) has announced the addition of the "Biometrics ... One major trend emerging in this ... biometric systems utilize more than one characteristic of an ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... 2008.- During the 1950s, Austrian and Swiss scientists conducted ... photographs of the glaciers, mountains and valleys. Around the ... months in the region at locations above 5000 metres, ... fifty years later, the black and white photographs taken ...
... to the IOF World Congress on Osteoporosis 2008, at ... 2008. To benefit from lower rates and ... registration fees are available for participants from non-OECD countries ... on-site registration, at higher rates, will be possible. ...
... the European Molecular Biology Laboratory (EMBL) have generated a ... of a vertebrate. With a newly developed microscope scientists ... the first 24 hours in the life of a ... representation of the embryo. The study, published in the ...
Cached Biology News:'Himalaya -- Changing Landscapes' photo exhibition draws attention to the impacts of climate change 2'Himalaya -- Changing Landscapes' photo exhibition draws attention to the impacts of climate change 3Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate 2
... Five cells (BTI-TN-5B1-4) derived from Trichoplusia ... shown to be capable of expressing ... proteins compared to other insect cells. ... features:- -Rapid doubling time as adherent cultures- Quick ...
... offers the most comprehensive, cost-effective solution ... have incorporated unprecedented quality into both ... includes proven detection chemistries and antibodies ... TechMate protocol. It also includes our ...
...
...
Biology Products: